Drugs / Rocklatan
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ROCKLATAN | — | 2019-03-12 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02674854 | Feb 2016 → Mar 2017 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07174401 | Jan → Dec 2026 expected | glaucoma | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07048886 Comparator | Jul 2025 → Dec 2026 expected | open-angle glaucoma | Center for Sight Las Vegas | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rocklatan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07174401 ↗ |
| Known as | PG324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02674854 ↗ |
| Action | Inhibit | “a Rho kinase inhibitor” NCT07048886 ↗ |
| Modality | Other / unclassified | “a fixed dose combination of a Rho kinase inhibitor and a prostaglandin analogue” NCT07048886 ↗ |
| Route | Other | “Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.” NCT07174401 ↗ |